Overview

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.
Phase:
N/A
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Antibodies
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Immunoglobulins
Melphalan
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus
Thiotepa